Structural Brain Magnetic Resonance Imaging to Rule Out Comorbid Pathology in the Assessment of Alzheimer’s Disease Dementia: Findings from the Ontario Neurodegenerative Disease Research Initiative (ONDRI) Study and Clinical Trials Over the Past 10 Years

Manuscript Number: 

19-1097R1

Author(s): 
Robert Bartha, Sara Berman Mitchell, Sandra E. Black, Michael Borrie, Elizabeth Finger, Corinne E. Fischer, Andrew Frank, Morris Freedman, Fuqiang Gao, Nathan Herrmann, Arunima Kapoor, Sanjeev Kumar, Jennifer Mandzia, Mario Masellis, Gary Naglie, Miracle Ozzoude, Stephen H. Pasternak, Bruce Pollock, Tarek K. Rajji, Joel Ramirez, William Reichman, Christopher J.M. Scott, Dallas Seitz, Richard H. Swartz, Sean Symons, David F. Tang-Wai, Carmela Tartaglia, Nicolaas Paul LG Verhoeff, Michael Uri Wolf

Disclosures

Robert Bartha

  • Nothing to Disclose

Sara Berman Mitchell

  • Nothing to Disclose

Sandra E. Black

  • Nothing to Disclose

Michael Borrie

  • Grants
    • Agency: 
      Biogen
      Dates: 
      2014-present
    • Agency: 
      Eli Lilly
      Dates: 
      2010-present
    • Agency: 
      Novartis
      Dates: 
      2017-2020
    • Agency: 
      Roche
      Dates: 
      2016-present
    • Agency: 
      Genentech
      Dates: 
      2010-present
    • Agency: 
      Eisai
      Dates: 
      2013-present
    • Agency: 
      Merck
      Dates: 
      2013-2019
    • Agency: 
      Sanofi
      Dates: 
      2010-2012
    • Agency: 
      Abbvie
      Dates: 
      2018-Present
    • Agency: 
      Lundbeck
      Dates: 
      2012-2016
    • Agency: 
      BMS
      Dates: 
      2012-2014

Elizabeth Finger

  • Consulting Fees:
    One time consulting fee from Biogen Canada for potential future phase 3 clinical trial for PSP.

Corinne E. Fischer

  • Grants
    • Agency: 
      Hoffman La Roche
      Dates: 
      2018-2022
    • Agency: 
      Vielight Inc
      Dates: 
      2019-2023

Andrew Frank

  • Nothing to Disclose

Morris Freedman

  • Patents/Royalties
    I am listed on a provisional patent related to methods and kits for differential diagnosis of Alzheimer’s disease vs frontotemporal dementia using blood biomarkers and may be listed on the planned patent application.

Fuqiang Gao

  • Nothing to Disclose

Nathan Herrmann

  • Nothing to Disclose

Arunima Kapoor

  • Nothing to Disclose

Sanjeev Kumar

  • Nothing to Disclose

Jennifer Mandzia

  • Nothing to Disclose

Mario Masellis

  • Consulting Fees:
    Consulting fees for: - Ionis Pharmaceuticals - Arkuda Therapeutics - Alector Pharmaceuticals

Gary Naglie

  • Nothing to Disclose

Miracle Ozzoude

  • Nothing to Disclose

Stephen H. Pasternak

  • Consulting Fees:
    Consultant for Zywie Bio LLC. For work on a proposed clinical trial of Ambroxol in Parkinson's Disease Dementia. This is no overlap of this work with the present study.

Bruce Pollock

  • Nothing to Disclose

Tarek K. Rajji

  • Nothing to Disclose

Joel Ramirez

  • Nothing to Disclose

William Reichman

  • Nothing to Disclose

Christopher J.M. Scott

  • Nothing to Disclose

Dallas Seitz

  • Grants
    • Agency: 
      Hoffmann La Roche
      Dates: 
      September 2017 - December 2019

Richard H. Swartz

  • Nothing to Disclose

Sean Symons

  • Nothing to Disclose

David F. Tang-Wai

  • Nothing to Disclose

Carmela Tartaglia

  • Nothing to Disclose

Nicolaas Paul LG Verhoeff

  • Nothing to Disclose

Michael Uri Wolf

  • Nothing to Disclose